1124P Lenvatinib + pembrolizumab (L + P) in participants (Pts) with advanced or recurrent endometrial cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes.
Saved in:
| Title: | 1124P Lenvatinib + pembrolizumab (L + P) in participants (Pts) with advanced or recurrent endometrial cancer (aEC): Study 309/KEYNOTE-775 and ENGOT-en9/LEAP-001 post-(neo)adjuvant therapy outcomes. |
|---|---|
| Authors: | Marth, C.1 (AUTHOR), Lorusso, D.2 (AUTHOR), Bidzinski, M.3 (AUTHOR), Salutari, V.4 (AUTHOR), Akıllı, H.5 (AUTHOR), Oaknin, A.6 (AUTHOR), Kaen, D.L.7 (AUTHOR), Nogueira-Rodrigues, A.8 (AUTHOR), Miller, D.S.9 (AUTHOR), Hasegawa, K.10 (AUTHOR), Mackay, H.11 (AUTHOR), Moore, R.G.12 (AUTHOR), Santin, A.D.13 (AUTHOR), Yunokawa, M.14 (AUTHOR), Ye, J.15 (AUTHOR), Slomovitz, B.M.16 (AUTHOR), McKenzie, J.17 (AUTHOR), Meng, R.18 (AUTHOR), Makker, V.19 (AUTHOR) |
| Source: | Annals of Oncology. 2025 Supplement 2, Vol. 36, pS748-S749. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2025.08.1760 |
